Revenue | $10 - $100 million See Exact Annual Revenue |
---|---|
Employees | 10 - 100Exact Company Size |
Primary Industry | 5411 Legal Services |
Address | 25 West Watkins Mill Road Suite A Gaithersburg, MD 20878 |
Arcellx | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
---|---|---|---|
2021 | Details in Premium Report | ||
2020 | |||
2019 | |||
2018 | |||
2017 |
1-Year Growth Rate: 3-Year Growth Rate (CAGR): | ![]() |
Date | Investors | Percent Raised | Target Size |
---|---|---|---|
April 9, 2021 | 31 | 100% | $115 MM |
Complete list of funding rounds and total amounts in the Company Report |
$ Millions (Industry Average) | |
---|---|
Arcellx Revenue (Sales) | ![]() |
Cost of Goods Sold | |
Gross Profit | |
Operating Expenses | |
Advertising | |
Salaries and wages | |
Other Operating Expenses | |
Total Operating Expenses | |
Operating Income | |
EBITDA | |
EBIT (Earnings Before Interest and Taxes) | |
Net Profit | |
Trademark | Date |
---|---|
ARC-SPARX Biological preparations for the treatment of cancer using genetically engineered cells; pharmaceutical preparations for targeting tissues based on select tissue markers and ligands; pharmaceutical preparations for the purpose of binding ligands using receptors; pharmaceutical preparations for immunotherapy using genetically engineered cells | 11/26/2021 |
SPARX PROTEIN Biological preparations for the treatment of cancer using polypeptides and genetically engineered cells; pharmaceutical preparations for targeting tissues based on select tissue markers and ligands; pharmaceutical preparations for the purpose of binding ligands using engineered polypeptides and receptors; pharmaceutical preparations for immunotherapy using polypeptides and genetically engineered cells; pharmaceutical preparations for immune cell therapy using polypeptides and genetically engineered cells | 04/06/2020 |
SPARX PROTEINS Biological preparations for the treatment of cancer using polypeptides and genetically engineered cells; pharmaceutical preparations for targeting tissues based on select tissue markers and ligands; pharmaceutical preparations for the purpose of binding ligands using engineered polypeptides and receptors; pharmaceutical preparations for immunotherapy using polypeptides and genetically engineered cells; pharmaceutical preparations for immune cell therapy using polypeptides and genetically engineered cells | 04/06/2020 |
Publisher: AnythingResearch
Company | Headquarters | Revenue ($ MM) |
---|---|---|
NC BAR ASSOC 401K PLAN | Cary, NC | 100 |
BAR ASSOCIATION OF ERIE COUNTY | Buffalo, NY | 6 |
UFCW LEGAL ASSISTANCE FUND | Atlanta, GA | 5 |
PROFESSIONAL LAW ENFORCEMENT A | Troy, MI | 2 |
LATHAM & WATKINS | Los Angeles, CA | 2 |
CHG COMPANIES | Midvale, UT | 2 |
BARNES & THORNBURG | Indianapolis, IN | 1 |
TROUTMAN PEPPER HAMILTON SANDERS | Atlanta, GA | 1 |
KIRKLAND & ELLIS | Chicago, IL | 1 |
Company | Headquarters | Revenue ($ MM) |
---|---|---|
BWW LAW GROUP | Rockville, MD | 100 |
SHULMAN ROGERS GANDAL PORDY & ECKER P A | Potomac, MD | 64 |
AUTOMATED PRECISION | Rockville, MD | 54 |
STEIN SPERLING BENNETT DE JONG DRISCOLL PC | Rockville, MD | 50 |
KVS TITLE | Bethesda, MD | 48 |
LERCH EARLY & BREWER CHARTERED | Bethesda, MD | 42 |
Company | Revenue ($ MM) |
---|---|
![]() |